A Study of CS-3150 to Evaluate Efficacy and Safety to in combination with ARB or ACE inhibitor in Hypertensive Patients with Moderate Kidney Dysfunction

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223233

Enrollment

Registered

2016-06-06

Start date

2016-06-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension with moderate renal impairment

Interventions

investigational material(s) Generic name etc : CS-3150 INN of investigational material : Esaxerenone Therapeutic category code : 214 Antihypertensives Dosage and Administration for Investigational mat

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ) Male and female subjects aged 20 or older to 80 years or younger at informed consent 2) Subjects with hypertension (i)Sitting SBP >= 140 mmHg, = 80 mmHg, = 30 mL/min/1.73m2 and < 60 mL/min/1.73m2 4) Treated with an ARB or ACE inhibitor

Exclusion criteria

Exclusion criteria: 1)Secondary hypertension (except renoparenchymal hypertension) or malignant hypertension 2)Diabetes mellitus with albuminuria 3)Subjects under Insulin treatment 4)Subjects under or pre-planned for hemodialysis 5)Serum potassium level = 4.8 mEq/L

Design outcomes

Primary

Measure	Time frame
safety efficacy - Change from baseline in sitting systolic and diastolic blood pressure at the end of treatment - Adverse events	—

Secondary

Measure	Time frame
efficacy -Time course of sitting systolic and diastolic blood pressure -Proportion of patients achieving sitting blood pressure control	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026